title: Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.
abstract: Aspergillus spp. cultured in specimens from the airways of chronic obstructive pulmonary disease (COPD) patients are frequently considered as a contaminant. However, growing evidence suggests that severe COPD patients are at higher risk of developing invasive pulmonary aspergillosis (IPA), although IPA incidence in this population is poorly documented. Some data report that COPD is the underlying disease in 1% of patients with IPA. Definitive diagnosis of IPA in COPD patients is often difficult as tissue samples are rarely obtained before death. Diagnosis is therefore usually based on a combination of clinical features, radiological findings (mostly thoracic computed tomography scans), microbiological results and, sometimes, serological information. Of 56 patients with IPA reported in the literature, 43 (77%) were receiving corticosteroids on admission to hospital. Breathlessness was always a feature of disease and excess wheezing was present in 79% of patients. Fever (>38 degrees C) was present in only 38.5%. Chest pain and haemoptysis were uncommon. Six out of 33 (18%) patients had tracheobronchitis observed during bronchoscopy. The median delay between symptoms and diagnosis was 8.5 days. The mortality rate was high: 53 out of 56 (95%) patients died despite invasive ventilation and antifungal treatment in 43 (77%) of them. In chronic obstructive pulmonary disease patients, invasive pulmonary aspergillosis currently carries a very poor prognosis. Outcome could perhaps be improved by more rapid diagnosis and prompt therapy with voriconazole.
authors: Intensive Care Unit, Mont-Godinne University Hospital, Université Catholique de Louvain, 5530, Yvoir, Belgium. pierre.bulpa@rean.ucl.ac.be
authors: P
authors: P
authors: Bulpa
authors: A
authors: A
authors: Dive
authors: Y
authors: Y
authors: Sibille
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000368:Aged; D000935:Antifungal Agents / Q000494:pharmacology; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000150:complications* / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality; D001230:Aspergillus / Q000378:metabolism*; D001999:Bronchoscopy / Q000379:methods; D005260:Female; D006801:Humans; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000382:microbiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality; D013183:Sputum / Q000382:microbiology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000935:Antifungal Agents